Market Research Logo

Incyte Corporation (INCY) - Financial and Strategic SWOT Analysis Review

Incyte Corporation (INCY) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Incyte Corporation (Incyte) is a biopharmaceutical company that discovers, develops, and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis as well as patients with polycythemia vera who are intolerant to hydroxyurea. In collaboration with Incyte, Novartis International Pharmaceutical Ltd. (Norvatis) develops and commercializes ruxolitinib outside the US for hematologic and oncologic indications under the name Jakavi. The company’s pipeline portfolio encompasses drug indications targeted at the treatment of lung cancer, graft versus host disease, non-small cell lung cancer, multiple tumor types, b-cell malignancies, solid tumors, glioblastoma, liver cancer, and advanced malignancies. The company operates in Switzerland, France, Germany, Italy, Spain, and Luxembourg. Incyte is headquartered in Wilmington, Delaware, the US.

Incyte Corporation Key Recent Developments

Aug 09, 2016: Incyte Reports 2016 Second-Quarter Financial Results and Updates Key Clinical Programs
May 09, 2016: Incyte Reports 2016 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
Apr 15, 2016: Incyte Investor Event at AACR 2016 to Highlight Innovative and Diversified Research and Development Portfolio
Feb 29, 2016: Incyte Joins Patient Organizations Worldwide in Recognition of Rare Disease Day 2016 to Make Patient Voices Heard
Feb 11, 2016: Incyte Reports 2015 Fourth-Quarter and Year-End Financial Results, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Incyte Corporation - Key Facts
Incyte Corporation - Key Employees
Incyte Corporation - Key Employee Biographies
Incyte Corporation - Major Products and Services
Incyte Corporation - Pharmaceutical Pipeline Products Data
Incyte Corporation, Pipeline Products by Therapy Area
Incyte Corporation, Pipeline Products by Development Phase
Incyte Corporation - History
Incyte Corporation - Company Statement
Incyte Corporation - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Incyte Corporation - Business Description
Incyte Corporation - Corporate Strategy
Incyte Corporation - SWOT Analysis
SWOT Analysis - Overview
Incyte Corporation - Strengths
Strength - Focused R&D Initiatives
Strength - Lead Product: Jakafi
Strength - Orphan Drug Designation
Incyte Corporation - Weaknesses
Weakness - Product Discontinuations
Weakness - Concentration of Customers
Incyte Corporation - Opportunities
Opportunity - Promising Product Pipeline
Opportunity - Strategic Initiatives
Opportunity - Market Potential: Rheumatoid Arthritis
Incyte Corporation - Threats
Threat - Lack of Manufacturing Facilities
Threat - Highly Competitive Environment
Threat - Stringent Government Regulations
Incyte Corporation - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Incyte Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Incyte Corporation, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Incyte Corporation, Recent Deals Summary
Section 5 – Company’s Recent Developments
Aug 09, 2016: Incyte Reports 2016 Second-Quarter Financial Results and Updates Key Clinical Programs
May 09, 2016: Incyte Reports 2016 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
Apr 15, 2016: Incyte Investor Event at AACR 2016 to Highlight Innovative and Diversified Research and Development Portfolio
Feb 29, 2016: Incyte Joins Patient Organizations Worldwide in Recognition of Rare Disease Day 2016 to Make Patient Voices Heard
Feb 11, 2016: Incyte Reports 2015 Fourth-Quarter and Year-End Financial Results, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs
Jan 11, 2016: Incyte Presents Significant Progress in its Development Portfolio
Nov 03, 2015: Incyte Reports 2015 Third-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
Aug 04, 2015: Incyte Reports 2015 Second-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
Jul 07, 2015: Incyte and Vanderbilt University Medical Center Establish Multi-Year Oncology Research Alliance
Jun 19, 2015: Incyte Announces Organizational and Management Changes to Drive Future Global Expansion
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Incyte Corporation, Key Facts
Incyte Corporation, Key Employees
Incyte Corporation, Key Employee Biographies
Incyte Corporation, Major Products and Services
Incyte Corporation, Number of Pipeline Products by Therapy Area
Incyte Corporation, Number of Pipeline Products by Development Stage
Incyte Corporation, Pipeline Products By Therapy Area and Development Phase
Incyte Corporation, History
Incyte Corporation, Subsidiaries
Incyte Corporation, Key Competitors
Incyte Corporation, Ratios based on current share price
Incyte Corporation, Annual Ratios
Incyte Corporation, Interim Ratios
Incyte Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Incyte Corporation, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Incyte Corporation, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Incyte Corporation, Pipeline Products by Therapy Area
Incyte Corporation, Pipeline Products by Development Phase
Incyte Corporation, Performance Chart (2011 - 2015)
Incyte Corporation, Ratio Charts
Incyte Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Incyte Corporation, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report